Favorable Response to Pembrolizumab After Durvalumab Failure in a Stage III Sarcomatoid Carcinoma of the Lung: A Case Report
BMC pharmacology & toxicology - United Kingdom
doi 10.1186/s40360-020-00404-7
Full Text
Open PDFAbstract
Available in full text
Date
April 3, 2020
Authors
Publisher
Springer Science and Business Media LLC